Oncology Central

APF530 (Granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy

0

Aim: APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV). We compared efficacy and safety of APF530 versus ondansetron for delayed CINV after highly emetogenic chemotherapy (HEC), following a guideline-recommended three-drug regimen. Methods: HEC patients received APF530 500 mg subcutaneously or ondansetron 0.15 mg/kg intravenously, with dexamethasone and fosaprepitant. Primary end point was delayed-phase complete response (CR: no emesis or rescue medication).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

You can also view key results from the MAGIC trial in our exclusive infographic.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.